Literature DB >> 21063848

Serum adiponectin and resistin levels in patients with polycystic ovarian syndrome and their clinical implications.

Yuxia Wang1, Xingmei Xie, Weijie Zhu.   

Abstract

In this study, serum adiponectin and resistin levels were determined in 46 patients with polycystic ovarian syndrome (PCOS), and their correlation with serum sexual hormones and insulin resistance (IR) were examined. The subjects included 26 obese patients with body mass index (BMI)>25 and 20 non-obese patients with BMI[Symbol: see text]25, with 25 obese and 25 non-obese healthy volunteers without PCOS serving as controls. Serum adiponectin and resistin levels in all subjects were measured, and endocrinal and metabolic indices were also analysed. Our results showed that the serum adiponectin levels in both obese and non-obese PCOS groups were significantly lower than their controls, while the serum resistin levels in obese and non-obese PCOS group were significantly higher than in their controls (P<0.001). The serum adiponectin level was significantly lower and serum resistin level significantly higher in the non-obese PCOS group as compared with the obese control group (P<0.05). Serum adiponectin level was negatively correlated with FIN, HOMA-IR, LH and LH/FSH (P<0.05), but serum resistin level was positively correlated with FIN, HOMA-IR, LH and LH/FSH (P<0.05). We are led to conclude that PCOS patients have obvious IR, low serum adiponectin and high serum resistin, and adiponectin and resistin might play important roles in the pathogenesis of IR in PCOS patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21063848     DOI: 10.1007/s11596-010-0556-8

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  19 in total

1.  Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome.

Authors:  A Dunaif; D T Finegood
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

Review 2.  Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ.

Authors:  P Trayhurn; J H Beattie
Journal:  Proc Nutr Soc       Date:  2001-08       Impact factor: 6.297

3.  Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin.

Authors:  W S Yang; W J Lee; T Funahashi; S Tanaka; Y Matsuzawa; C L Chao; C L Chen; T Y Tai; L M Chuang
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

4.  Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.

Authors:  C Weyer; T Funahashi; S Tanaka; K Hotta; Y Matsuzawa; R E Pratley; P A Tataranni
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

Review 5.  Treatment of the adolescent patient with polycystic ovary syndrome.

Authors:  Samantha M Pfeifer; Molina Dayal
Journal:  Obstet Gynecol Clin North Am       Date:  2003-06       Impact factor: 2.844

6.  Defects in beta-cell function in functional ovarian hyperandrogenism.

Authors:  N M O'Meara; J D Blackman; D A Ehrmann; R B Barnes; J B Jaspan; R L Rosenfield; K S Polonsky
Journal:  J Clin Endocrinol Metab       Date:  1993-05       Impact factor: 5.958

7.  Insulin resistance, obesity, hypofibrinolysis, hyperandrogenism, and coronary heart disease risk factors in 25 pre-perimenarchal girls age < or =14 years, 13 with precocious puberty, 23 with a first-degree relative with polycystic ovary syndrome.

Authors:  Charles J Glueck; John A Morrison; Ping Wang
Journal:  J Pediatr Endocrinol Metab       Date:  2008-10       Impact factor: 1.634

8.  Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.

Authors:  Bülent O Yildiz; Hakan Yarali; Havva Oguz; Miyase Bayraktar
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

9.  Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study.

Authors:  Sarah C Kent; Carol L Gnatuk; Allen R Kunselman; Laurence M Demers; Peter A Lee; Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2008-02-12       Impact factor: 5.958

10.  Hyperinsulinaemia in the polycystic ovary syndrome confirmed with a specific immunoradiometric assay for insulin.

Authors:  G S Conway; P M Clark; D Wong
Journal:  Clin Endocrinol (Oxf)       Date:  1993-02       Impact factor: 3.478

View more
  6 in total

Review 1.  Multiomics Analysis-Based Biomarkers in Diagnosis of Polycystic Ovary Syndrome.

Authors:  Shikha Rani; Piyush Chandna
Journal:  Reprod Sci       Date:  2022-01-27       Impact factor: 3.060

2.  Impact of metabolic disorders on endometrial receptivity in patients with polycystic ovary syndrome.

Authors:  Can Wang; Yang-Xing Wen; Qing-Yun Mai
Journal:  Exp Ther Med       Date:  2022-01-14       Impact factor: 2.447

3.  MIF May Participate in Pathogenesis of Polycystic Ovary Syndrome in Rats through MAPK Signalling Pathway.

Authors:  Dan-Ni Zhou; Sai-Jiao Li; Jin-Li Ding; Tai-Lang Yin; Jing Yang; Hong Ye
Journal:  Curr Med Sci       Date:  2018-10-20

4.  Evidence for decreased expression of APPL1 associated with reduced insulin and adiponectin receptors expression in PCOS patients.

Authors:  R Dehghan; M Saidijam; N Shabab; M Yavangi; T Artimani
Journal:  J Endocrinol Invest       Date:  2016-04-13       Impact factor: 4.256

Review 5.  New markers of insulin resistance in polycystic ovary syndrome.

Authors:  K Polak; A Czyzyk; T Simoncini; B Meczekalski
Journal:  J Endocrinol Invest       Date:  2016-07-29       Impact factor: 4.256

6.  Circulating resistin and follistatin levels in obese and non-obese women with polycystic ovary syndrome: A systematic review and meta-analysis.

Authors:  Tahereh Raeisi; Hossein Rezaie; Mina Darand; Akram Taheri; Nazila Garousi; Bahman Razi; Leonardo Roever; Reza Mohseni; Shimels Hussien Mohammed; Shahab Alizadeh
Journal:  PLoS One       Date:  2021-03-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.